Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US-2016152693-A1 · Jun 2, 2016 · US
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US9803001B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9803001-B2 |
| Application number | US-201414499772-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 29, 2014 |
| Priority date | Jun 5, 2009 |
| Publication date | Oct 31, 2017 |
| Grant date | Oct 31, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
First claim
Opening claim text (preview).
The invention claimed is: 1. Polypeptide comprising or essentially consisting of SEQ ID NO: 53, wherein the first Glutamic acid has been changed into Aspartic acid, and in which optionally in at least one VHH that forms part of SEQ ID NO: 53, one or more amino acid residues have been mutated selected from the following: Val5Leu, Ala14Pro, Ser19Arg, Ile20Leu, Glu44Gly, Ala74Ser, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp. 2. Polypeptide according to claim 1 , comprising or essentially consisting of SEQ ID NO: 53, in which in at least one VHH that forms part of SEQ ID NO: 53, following amino acid residue(s) have been mutated: Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu; Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu; Gly78Leu, Ala83Arg, Asp85Glu and Arg105Gln; Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp; Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp; Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gly54Asp; Gly54Asp; Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln; or Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln; Glu1Asp; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln; or Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln. 3. Polypeptide according to claim 1 , in which in at least two VHHs that form part of SEQ ID NO: 53, one or more amino acid residues have been mutated selected from the following: Val5Leu, Ala14Pro, Ser19Arg, Ile20Leu, Glu44Gly, Ala74Ser, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp. 4. Polypeptide according to claim 1 , in which in all three VHHs that form part of SEQ ID NO: 53, one or more amino acid residues have been mutated selected from the following: Val5Leu, Ala14Pro, Ser19Arg, Ile20Leu, Glu44Gly, Ala74Ser, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp. 5. Polypeptide according to claim 2 , in which in at least two VHHs that form part of SEQ ID NO: 53, following amino acid residue(s) have been mutated: Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu; Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu; Gly78Leu, Ala83Arg, Asp85Glu and Arg105Gln; Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp; Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp; Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gly54Asp; Gly54Asp; Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln; or Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln; Glu1Asp; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln; or Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln. 6. Polypeptide according to claim 2 , in which in all three VHHs that forms part of SEQ ID NO: 53, following amino acid residue(s) have been mutated: Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu; Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu; Gly78Leu, Ala83Arg, Asp85Glu and Arg105Gln; Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp; Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp; Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gly54Asp; Gly54Asp; Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln; Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln; or Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln; Glu1Asp; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln; Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln; or Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln.
Assignees
Inventors
Classifications
for RNA viruses · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Antitussive agents · CPC title
for throat disorders · CPC title
Antiasthmatics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9803001B2 cover?
- Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an impro…
- Who is the assignee on this patent?
- Ablynx Nv
- What technology area does this patent fall under?
- Primary CPC classification C07K16/11. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).